BPC 157 Stable Therapeutic indications
We are searching for active molecules in the human body for better ways of healing and preventing diseases. We aim to improve understanding of the human body own healing processes and healing molecules from the human body to improve standards of care or establish new ones in healing humans.
At Diagen Company we believe that the immune system, its own healing agents and human body own healing molecules are the fundamental drivers for preventing and curing diseases.
Our goal is to translate our discovery of Body Protecting Compound (BPC) and our BPC 157 Stable into therapies for various diseases to cure patients.
Based on positive results in our animal studies with BPC 157 Stable we have determined the following indications of BPC 157 Stable which would be further needed to evaluate on Clinical trials:
BPC 157 and Gastrointestinal tract related diseases; Chron's disease and gastric tract diseases
Gastrointestinal tract related disease, Chron’s disease, ulcers in any part of the gastrointestinal tract, general anti-inflammatory activity, gastrointestinal inflammatory disease, acute pancreatitis
In studies we have demonstrated that BPC 157 may equally counteract both COX-1 and COX-2 inhibition (counteracting the noxious effects of standard NSAIDs and celecoxib on all lesions) and additional NOS blockade. Published in Eur J Pharmacol, Life Sci, Dig Dis Sci, World J Gastroenterology, Plos One.
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Gastrointestinal lesions healing
(lesions induced by NSAIDs, alcohol, cytostatic drugs)
| Positive |
In studies we have demonstrated that BPC 157 may equally counteract both COX-1 and COX-2 inhibition (counteracting the noxious effects of standard NSAIDs and celecoxib on all lesions) and additional NOS blockade. Published in Eur J Pharmacol, Life Sci, Dig Dis Sci, World J Gastroenterology, Plos One.
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Duodenal ulcers healing
| Positive |
Therapy with BPC 157 Stable reduced duodenal lesions with evident healing effect. Published in Eur J Pharmacol, J Physiol, Inflammopharmacology.
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Ischemia and reperfusion colitis healing
| Positive |
In the study we have obtained new insights in treatment of colitis and ischemia and reperfusion in rats using stable gastric pentadecapeptide BPC 157. BPC 157 proved to be a fundamental treatment that quickly restores blood supply to the chemically injured area and rapidly activates collaterals and counteracts reperfusion injury. This effect involves the NO system. Published in World J Gastroenterology.
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Fistula healing (external and internal) | Positive |
BPC 157 Stable produces simultaneous healing of different tissues, thereby, it exhibits also excellent healing of fistulas, external and internal, colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, colovesical, and rectovaginal. Published in J Pharm Sci, Eur J Pharmacol, Life Si, Dig Dis Sci, Cur Pharm Des, Biomedicines.
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Liver Cirrhossis abd Fibrosis healing
| Positive |
BPC 157 therapy can prevent liver cirrhosis development and portal hypertension and counteracts pre-existing cirrhosis and portal hypertension by attenuating/counteracting the piecemeal necrosis, focal lyric necrosis, apoptosis, and focal inflammation, disturbed cell proliferation (Ki-67-staining), cytoskeleton structure in the hepatic satellite cell (α-SMA staining). Thus, BPC 157 may counteract liver fibrosis. Published in Euro J Pharmacology
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Therapy for Acute Pancreatis healing
| Positive |
BPC 157 therapy counteracted bile duct occlusion-induced acute pancreatitis and decreased for almost 50% of amylase level. Besides, BPC 157 therapy counteracted also concomitant vascular and multi-organ failure that rats cannot sustain, and succumbed to injury course. As particular rescue appeared collateral rescuing pathways, the azygos vein, direct blood flow delivery Published in Biomedicines, Digestive Diseases and Sciences.
BPC 157 organoprotective activity
Organoprotective activity: protection of hepatic and pancreatic lesions, protection of endothelial cells, prevention of adhesion formation, prevention and treatment of myocardial infarction and brain stroke, protective effect in immune system
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Therapy for Myocardial infarction and prevention
(Heart, Pulmoary Hypertension, Thrombosis) | Positive |
The stable gastric pentadecapeptide BPC 157, was useful peptide therapy against isoprenaline myocardial infarction, as well as against isoprenaline myocardial reinfarction. Published in Biomedicines.
BPC 157 for treatment of viral infections
Treatment of viral infections, particularly with West Nile, Dengue types 1-4, hepatitis A virus, herpes strain influenza A virus and ARBO viruses, such as tick borne encephalitis, cytomegalovirus CMV and LCM virus, feline leukemia virus
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Virus infections healing (TBE, Bhania Denge 1, Denge 2, Denge 3, Denge 4, Sindbis, West Nile, Čalovo, Hepatitis A, LCM, Herpes HSV-1, Fe-LV -Feline leukemia virus) | Positive |
Studies described in DIAGEN Patents. More information available on request for Investors.
BPC 157 for accelerated healing of Burns
Accelerated healing of burns
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Burns healing Skin burns healing | Positive |
BPC 157 Stable (no reported toxicity (LD1 not achieved)) therapy wound healing is reviewed, focusing on the particular skin wound therapy, incision/excision wound, deep burns, diabetic ulcers, and alkali burns, which may be generalized to other tissues healing. Poor healing can be reversed by BPC 157 cream application. Published in Frontiers in Pharmacology, Burns.
BPC 157 for accelerated healing of wounds and nerve linkages
Accelerated healing of wounds, muscle, tendon, ligament, regeneration of ruptured nerve linkages
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Wounds healing (Wounds, Fistulas, Perforation, Skin Defects) | Positive |
In BPC 157 studies, reviewed was a particular skin wound therapy, incision/excision wound, diabetic ulcers, etc. which may be generalized to other tissues healing. Besides, the fully accomplished wound healing means that all four events, the vessel constriction, the primary platelet plug, the fibrin mesh which acts to stabilize the platelet plug, and the resolution of the clot, were all distinctively affected given the healing improvement by BPC 157 therapy in either early course or late course of wound healing. Published in Frontiers in Pharmacology, Journal of Physiology-Paris, etc.
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Muscles, ligaments and junctions healing (Muscle Crush, Muscle Transection, Myotendinous Junctions) | Positive |
Recovery of the myotendinous junction after detachment of quadriceps muscle from quadriceps muscle tendon and full function recovery can be seen as combined results of the previous recovering effect on muscle disturbances (muscle transection, crush, denervation) and tendon (transection, detachment, osteotendon junction recovery). Published in Biomedicines, Journal of Orthopaedic Research, Surgery Today.
BPC 157 for healing Achilles' tendon injury
Accelerated healing of bone fractures, Achilles’ tendon
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Achilles’ tendon accelerated healing
| Positive |
BPC 157 therapy of Achilles tendon healing means the tendon recovery without ossicle formation after tendon transection as well as after tendon detachment from the bone, and osteotendon junction reestablishment. The bone healing effect includes bone recovery following severe pseudoarthrosis and bone loss. Published in Journal of Orthopaedic Research
BPC 157 for healing spinal cord injury
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Spinal cord injury healing
| Positive |
In Studies for Spinal cord injury healing we have demonstrated rapid and sustained recovery (1 year) and in addition we showed the particular points of the immediate effect of the BPC 157 therapy that began rapidly after its administration. Published in Current Issues in Molecular Biology, Journal of Orthopaedic Research
BPC 157 for treatment of hypertension
Treatment of organic disorders associated with NO formation: hypertension, hypotension, anaphylaxis, circulatory and septic shock, aggregation of thrombocytes
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Hypertension treatment and healing (Blood pressure, Lungs hypertension, Pyloric sphincters) | Positive |
BPC 157 therapy exerts the NO release of its own as a modulator controlling effect and substantiates the counteraction of the adverse effects of either NOS blockade or NOS over-stimulation. In particular, for a vascular recovery, there was the counteraction of L-NAME-hypertension and the pro-thrombotic effect as well as the counteraction of L-arginine-hypotension and the anti-thrombotic effect. It is likely that these counteractions might also have occurred due to the particular effect on thrombocyte function maintenance without affecting coagulation pathways, particularly controlling vasomotor tone through the activation of the Src-Caveolin-1-eNOS pathway (note, pulmonary arterial hypertension was also counteracted. Published in Biomedicines, The European Journal of Pharmacology.
BPC 157 for treatment of neurological diseases and disorders; Multiple sclerosis, Parkinson disease model, encephalopathy’s, etc.
Treatment of neurological diseases and disorders: Multiple sclerosis, myasthenia gravis, lupus erythematosus, neuropathy, dysfunction of somatosensory nerves, asthma, rhinitis, pemphigus and eczema
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Neurological diseases treatment and healing (Multiple sclerosis, Parkinson’s disease model, Encephalopathy, Central nervous system, Catalepsy, Dopamine system, Morphine-induced analgesia, Diazepam tolerance and physical dependence reduction) | Positive |
These were the behavioral findings (interaction with main systems, anxiolytic, anticonvulsive, antidepressant effect, counteracted catalepsy, and positive and negative schizophrenia symptoms models). Muscle healing and function recovery appeared as the therapeutic effects of BPC 157 on the various muscle disabilities of a multitude of causes, both peripheral and central (i.e. in multiple sclerosis model (cuprizone), and Parkinson’s disease (Parkinsogenic neurotoxin MPTP and reserpine). Published in Journal of Physiology-Paris, etc.
BPC 157 for reorganization of rapid blood recirculation
Therapy in all conditions, in which rapid reorganization of blood circulation is mandatory
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Rapid blood recirculation (Occlusion of the inferior caval vein blood recirculation, Occluded Superior Mesenteric Artery and Vein, Primary Abdominal Compartment Syndrome, Venous occlusion) | Positive |
Myocardinal infarction & Brain stroke
BPC 157 therapy by rapidly activated collateral pathways counteracted the vascular and multi organ failure concomitant to major vessel occlusion and, similar to noxious procedures reversed the initiated multicausal noxious circuit of the occlusion/occlusion-like syndrome. Severe intracranial (superior sagittal sinus) hypertension, portal and caval hypertensions, and aortal hypotension were attenuated/eliminated. Counteracted were the severe lesions in the brain, lungs, liver, kidney, and gastrointestinal tract. In particular, progressing thrombosis, both peripherally and centrally, and heart arrhythmias and infarction that would consistently occur were fully counteracted and/or almost annihilated. Published in Biomedicines, World J Gastroenterol, Pathophysiology
Healing eye diseases
Treatment of Glaucoma, Retinal Ischemia, Corneal ulcer therapy
Study Drug | Indication | Study results |
|---|---|---|
BPC 157 Stable – DIAGEN | Healing eye disturbances (Corneal ulcer therapy, Glaucoma, Retinal Ischemia) | Positive |
We revealed BPC 157 stable cytoprotective therapy with strong vascular rescuing capabilities in glaucoma therapy. With these capabilities, BPC 157 Stable therapy can recover glaucoma, normalize intraocular pressure, maintain retinal integrity, recover pupil function, recover retinal ischemia, and corneal injuries, maintain transparency after complete corneal abrasion, corneal ulceration, and counteract dry eye after lacrimal gland removal or corneal insensitivity. Published in Front Pharmacol, Pharmaceuticals, Exp Eye Res, Biomedicines.
